Antineoplastic effect of a novel chemopreventive agent, neokestose, on the Caco-2 cell line via inhibition of expression of nuclear factor-κB and cyclooxygenase-2

Lee,Shun‑Mei; Chang,Jan‑Yi; Wu,Jiann‑Shing; Sheu,Dey‑Chyi

doi:10.3892/mmr.2015.3507

Antineoplastic effect of a novel chemopreventive agent, neokestose, on the Caco-2 cell line via inhibition of expression of nuclear factor-κB and cyclooxygenase-2

Authors:
- Shun‑Mei Lee
- Jan‑Yi Chang
- Jiann‑Shing Wu
- Dey‑Chyi Sheu
View Affiliations

Affiliations: Department of Bioengineering, Tatung University, Taipei 104, Taiwan, R.O.C., Department of Styling and Cosmetology, Hsin Shen Junior College of Medical Care and Management, Taoyuan 325, Taiwan, R.O.C.
Published online on: March 18, 2015 https://doi.org/10.3892/mmr.2015.3507
Pages: 1114-1118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neokestose is a 6G-fructooligosaccharide (FOS) and an important prebiotic. When FOS are ingested by patients with colorectal cancer, they may come into contact with cancer cells prior to being fermented by bifidobacteria in the colon. In the present study, the effects of neokestose on cell proliferation, cell cycle and apoptosis of the colorectal cancer cell line Caco‑2 were investigated to evaluate its anti‑cancer effect. An MTT assay showed that neokestose‑treated Caco‑2 cells exhibited a significant and dose‑dependent loss of viability. Flow cytometric analysis indicated that the sub‑G1 population of Caco‑2 cells was significantly increased following treatment with neokestose, and the percentage of Caco‑2 cells in the stage of late apoptosis was also significantly increased in a dose‑dependent manner. Western blot analysis showed that the overexpression of nuclear factor‑κB, a central molecule responsible for the transition from inflammation to cancer, and cyclooxygenase‑2, an important enzyme in colorectal tumorigenesis, in colorectal carcinoma cells was inhibited by neokestose. Accordingly, the present study provided in vitro evidence that neokestose may be used as a dietary chemopreventive agent, whose application is more rational than that of COX-2 inhibitors or aspirin for preventing colorectal cancer.

View Figures

View References

1	Pisani P, Bray F and Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 97:72–81. 2002. View Article : Google Scholar : PubMed/NCBI
2	Arber N and Levin B: Chemoprevention of colorectal cancer: ready for routine use? Curr Top Med Chem. 5:517–525. 2005. View Article : Google Scholar : PubMed/NCBI
3	Dvory-Sobol H and Arber N: Cyclooxygenase-2 as target for chemopreventive interventions: new approaches. Cancer Biomark. 3:153–161. 2007.PubMed/NCBI
4	Manzano A and Pérez-Segura P: Colorectal cancer chemo-prevention: is this the future of colorectal cancer prevention? Scientific World Journal. 2012:327–341. 2012. View Article : Google Scholar
5	Temraz S, Mukherji D and Shamseddine A: Potential targets for colorectal cancer prevention. Int J Mol Sci. 14:17279–17303. 2013. View Article : Google Scholar : PubMed/NCBI
6	Pool-Zobel B, van Loo J, Rowland I and Roberfroid MB: Experimental evidences on the potential of prebiotic fructans to reduce the risk of colon cancer. Brit J Nutr. 87(Suppl 2): 273–281. 2002. View Article : Google Scholar
7	Swennen K, Courtin CM and Delcour JA: Non-digestible oligosaccharides with prebiotic properties. Crit Rev Food Sci Nutr. 46:459–471. 2006. View Article : Google Scholar : PubMed/NCBI
8	Sabater-Molina M, Larque E, Torrella F and Zamora S: Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem. 65:315–328. 2009. View Article : Google Scholar
9	Vargas AJ and Thompson PA: Diet and nutrient factors in colorectal cancer risk. Nutr Clin Pract. 27:613–623. 2012. View Article : Google Scholar : PubMed/NCBI
10	Oku T, Tokunaga T and Hosoya N: Nondigestibility of a new sweetener, ‘Neosugar’ in the rat. J Nutr. 114:1574–1581. 1984.PubMed/NCBI
11	Hidaka H, Eida T, Takizawa T, Tokunaga T and Tashiro Y: Effects of fructooligosaccharides on intestinal flora and human health. Bifidobacteria Microflora. 5:37–50. 1986. View Article : Google Scholar
12	Ooi LG and Liong MT: Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci. 11:2499–2522. 2010. View Article : Google Scholar : PubMed/NCBI
13	Maiorano AE, Piccoli RM, da Silva ES and de Andrade Rodrigues MF: Microbial production of fructosyltransferases for synthesis of prebiotics. Biotechnol Lett. 30:1867–1877. 2008. View Article : Google Scholar : PubMed/NCBI
14	de Abreu M, Alvaro-Benito M, Sanz-Aparicio J, Plou FJ, Fernandez-Lobato M and Alcalde M: Synthesis of 6-kestose using an efficient β-fructofuranosidase engineered by directed evolution. Adv Synth Catal. 355:1698–1702. 2013. View Article : Google Scholar
15	Sheu DC, Chang JY, Chen YJ and Lee CW: Production of high-purity neofructooligosaccharides by culture of Xanthophyllomyces dendrorhous. Bioresour Technol. 132:432–435. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kilian S, Kritzinger S, Rycroft C, Gibson G and du Preez J: The effects of the novel bifidogenic trisaccharide, neokestose, on the human colonic microbiota. World J Microbiol Biotechnol. 18:637–644. 2002. View Article : Google Scholar
17	Lim JS, Lee JH, Kang SW, Park SW and Kim SW: Studies on production and physical properties of neo-FOS produced by co-immobilized Penicillium citrinum and neo-fructosyltransferase. Eur Food Res Technol. 225:457–462. 2007. View Article : Google Scholar
18	Linde D, Rodríguez-Colinas B, Estévez M, Poveda A, Plou FJ and Fernández-Lobato M: Analysis of neofructooligosaccharides production mediated by the extracellular β-fructofuranosidase from Xanthophyllomyces dendrorhous. Biores Technol. 109:123–130. 2012. View Article : Google Scholar
19	Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2:301–310. 2002. View Article : Google Scholar : PubMed/NCBI
20	Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:803–809. 1996. View Article : Google Scholar : PubMed/NCBI